Reagencie a kity pro detekci COVID-19


  • FastGene® NGS-Library Quantification Kit -The accurate quantification of next-generation sequencing (NGS) Illumina® Libraries is very important for maximizing data output and quality on every sequencing run. The FastGene® NGS-Library Quantification Kit contains all reagents for an accurate and reproducible qPCR-based quantification of  Illumina® Libraries: The Kit comes with specific primers, qPCR Master Mix and DNA Standards.
  • PCRBIO HS VeriFi™ Polymerase - is a versatile and robust proofreading enzyme with AptaLock™ hot start technology for highly precise PCR. Improved DNA binding and increased processivity give significant improvements in speed, yield and sensitivity while also increasing PCR success rates of long and challenging templates.

  • PCRBIO VeriFi Polymerase - 100x higher fidelity than Taq DNA polymerase. Robust high fidelity enzyme engineered for all PCR applications where greater sequence accuracy is required, such as cloning, site-directed mutagenesis and sequencing

  • Hledáme posilu do našeho týmu na místo ochodního zástupce - více informací zde

    •   NEXT GENERATION KITY pro izolaci nuklových kyselin od firmy BioECHO-nová technologie- významně méně kroků ve srovnání s protokoly "bind–wash–elute" (o 50-70% méně kroků) a tím drasticky zkrácený čas potřebný k izolaci (2-5xrychlejší, v závislosti na aplikaci)


    RIDA®GENE SARS-CoV-2 CE IVD Zobrazit větší



    Cena: Na vyžádání

    Položit dotaz

    Více informací

    The reagents provided in the kit are sufficient for 100 determinations.

    RIDA®GENE SARS-CoV-2 is a multiplex real-time RT-PCR for the direct qualitative detection of novel Coronavirus (SARS-CoV-2) RNA from human respiratory samples. It is intended to be used by professional personnel in hospital laboratories, reference laboratories, private laboratories or state laboratories.

    With this test method, laboratories can analyze up to 96 samples simultaneously in less than two hours. Only one sample analysis is required for each patient, making it suitable for fast diagnostic assistance under increased throughput conditions.

    Please follow this link for an information about our 1-target strategy of the RIDA®GENE SARS-CoV-2 test 

    Benefits of CE-IVD RIDA®GENE SARS-CoV-2:

    • Best performance in the WHO assay comparison
    • Maximum sensitivity and specificity
    • Economically reasonable due to one target detection, no confirmation testing needed
    • Rapid process as time-to-result takes only 70 minutes

    Can be combined with all other RIDA®GENE assays in one run.